Tenofovir-containing nucleoside/nucleotide - Only antiretroviral maintenance therapy: Decision making and virological outcome

HIV Clinical Trials

Volumn 7, Issue 2, 2006, Pages 48-54

  Buehlmann, Manuela ^a   Chave, Jean Philippe ^b   Flepp, Markus ^c   Schiffer, Veronique ^d   Keiser, Olivia ^e   Furrer, Hansjakob ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b La Source Hospital   (Switzerland)

^c KLINIK IM PARK   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antiretroviral therapy; Desicion making; HIV; Resistance; Simplified maintenance therapyTenofovir; Viral failure

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DISEASE TRANSMISSION; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAINTENANCE THERAPY; MALE; MEDICAL DECISION MAKING; MONOTHERAPY; NONHUMAN; PHYSICIAN; POLYPHARMACY; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS INHIBITION; VIRUS RESISTANCE;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PHOSPHONIC ACIDS; PHYSICIANS; QUESTIONNAIRES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 33746117527     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/D0WD-ARAU-U1EF-30MM     Document Type: Article

References (29)

1. Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. J Acquir Immune Defic Syndr. 2003; 33(1):15-21.
2. Fung HB, Stone EA, Piacenti FJ. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin Ther. 2002;24(10):1515-1548.
3. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002; 16(9):1257-1263.
4. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS. 2002;16(9):1227-1235.
5. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191-201.
6. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251-260.
7. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004;189(7):1185-1192.
8. Podzamczer D, Ferrer E, Gatell JM, et al. Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antivir Ther. 2005;10(1):171-177.
9. Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis. 2005;192(11):1921-1930.
10. Hoogewerf M, Regez RM, Schouten WE, Weigel HM, Frissen PH, Brinkman K. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet. 2003;362(9400):1979-1980.
11. Perez-Elias MJ, Moreno S, Gutierrez C, et al. High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir. AIDS. 2005;19(7):695-698.
12. Sudre P, Rickenbach M, Taffé P, et al. Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988-2000. Schweiz Med Wochenschr. 2000;130(41):1493-1500.
13. Mauss S, Milinkovic A, Hoffmann C, et al. Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine. AIDS. 2005;19(1):101-102.
14. Masquelier B, Tamalet C, Montes B, et al. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir Ther. 2004;9(3):315-323.
15. McColl DJ, Margot NA, Wulfsohn M, Coakley DF, Cheng AK, Miller MD. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. J Acquir Immune Defic Syndr. 2004;37(3):1340-1350.
16. Miller MD. K65R, TAMs and tenofovir. AIDS Rev. 2004;6(1):22-33.
17. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004;189(5):837-846.
18. DeChristoforo R, Penzak SR. Tenofovir: a nucleoticle analogue reverse-transcriptase inhibitor for treatment of HIV infection. Am J Health Syst Pharm. 2004;61(1):86-98.
19. Garcia-Lerma JG, MacInnes H, Bennett D, et al. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol. 2003;77(10):5685-5693.
20. Valer L, Martin-Carbonero L, De Mendoza C, Corral A, Soriano V. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations. AIDS. 2004;18(15):2094-2096.
21. Torti C, Quiros-Roldon E, Regazzi M, et al. Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. Antivir Ther. 2005;10(4):505-513.
22. Parikh UM, Koontz DL, Chu CK, Schinazi RF, Mellors JW. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother. 2005;49(3):1139-1144.
23. Wirden M, Marcelin AG, Simon A, et al. Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients. J Med Virol. 2005;76(3):297-301.
24. Delaunay C, Brun-Vezinet F, Landman R, et al. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J Virol. 2005;79(15):9572-9578.
25. Latham V, Stebbing J, Mandalia S, et al. Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol. J Antimicrob Chemother. 2005;56(1):186-189.
26. Moyle G, Higgs C, Teague A, et al. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Antivir Ther. 2006;11(1):73-78.
27. Stefanski KE, Tracy CS, Upshur RE. Sources of evidence in HIV/AIDS care: pilot study comparing family physicians and AIDS service organization staff. BMC Health Serv Res. 2004;4(1):18.
28. Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis. 2002;185(9):1251-1260.
29. Opravil M, Baumann D, Chave JP, et al. Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. AIDS. 2004; 18(16):2213-2215.